Clinical Trial Update: RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating RC48 in combination with radiotherapy for HER2-expressing high-risk non-muscle invasive bladder cancer patients without visible di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• RC48 (disitamab vedotin)

Snippet

Sponsor: Peking University First Hospital | Conditions: HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT | Phase 2 | Status: NOT_YET_RECRUITING